Fed Week The Fed meets this week and will announce a decision on interest rates. Spoiler alert: essentially no one thinks a rate cut is likely. Meanwhile, it's another peak week for corporate earnings. Companies have been weighing-in about how tariffs will impact their individual businesses. Last week, the Dow Jones Industrial Average and the S&P 500 both gained 3.0% while the Nasdaq rose 3.4%. All three indices are still negative for the year. So far in 2025, the Dow and the S&P 500 are down 3%, and the Nasdaq has lost 7%. The earnings calendar this week includes Ford, Palantir Technologies, ON Semiconductor, Tyson Foods, Mattel, and Clorox on Monday; Marriott International and Super Micro Computer on Tuesday; Walt Disney, Uber, Door Dash, and Novo Nordisk on Wednesday; and Anheuser-Busch, Warner Bros. Discover, and Cloudflare on Thursday. So far, 65% of S&P 500 companies have reported and earnings are up 13% from the prior-year quarter. That is far above the consensus that called for EPS growth of about 3%-8% and follows 17% growth in 4Q24 EPS and 9% growth in 3Q24, according to LSEG. For the current quarter, Healthcare is the leading sector, with earnings up 45%, and Energy is the bottom, down 18%. On the economic calendar, the big event is the Fed's rate decision comes on Wednesday. Odds are only at 3% for a rate cut, according to the CME FedWatch rate tool. In other economic news, the ISM Services Index will be reported on Monday and the U.S. Trade Deficit will be updated on Tuesday. The Economic Call of the Week from Argus' Chief Economist Chief Graja is the ISM Services Index. Chris expects the index for April to remain above 50, indicating continuing expansion, and offered the following thoughts. 'This indicator has massive importance because it is one of the few that focuses on the dominant sector of the U.S. economy. The 'steady Eddie' services category represents a massive 47% of GDP and may be an important line of defense against further GDP contraction as the drag from imports should moderate. Services grew 2.4% in 1Q and contributed 1.1 point of growth that offset the quarterly decline in GDP. ISM Index values above 50 indicate that the services sector is generally expanding. March's reading was 50.8. Our estimate for April is 50.2. Consensus is 50.4.' Turning to other data, the Atlanta Fed GDPNow measure forecasts 1.1% for 2Q. This follows the surprise decline of 0.3% for 1Q GDP printed last week. The Cleveland Fed Inflation Nowcast forecasts a 2.2% rate for CPI in May, which is lower than the April rate and close to the Fed's 2.0% target. Mortgage rates ticked down by 5 basis points (bps) last week, with the average 30-year fixed-rate mortgage now at 6.76%, according to FreddieMac. Gas prices fell a penny to an average of $3.13 per gallon for regular gas. After this week, the Fed's next meeting is on June 18, with odds at 42% for a rate cut (lower than last week's odds), according to the CME FedWatch rate tool. After that, the Fed meets on July 30 and odds for a cut jump to 89%.

Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is based in Foster City, California. It has operations in more than 40 countries and more than 18,000 employees.

Continuing our analysis of bitcoin from Wednesday, the crypto currency looks to have completed a five-wave decline (with the lows in early April) and has broken its bear-market trendline off the peaks since earlier this year. In addition, price has jumped above initial chart resistance at $89,000, with the next piece of resistance as well as the important 61.8% retracement of the bear market at $96,000. If that resistance is taken out, we could see a move back to (at least) the all-time highs just above $109,000. For any asset in a powerful long-term bull market, it is critical that the longer timeframes also look bullish -- and that is certainly the case here. On the weekly chart, bitcoin traced out a bullish flag back to its 50-week moving average from January until April. The break out of the flag during the past two weeks has been strong and has confirmed the completion of the flag, which is a continuation pattern. Bullish flags are very common during a powerful uptrend and give an asset time to rest, regroup, and unravel both extreme overbought momentum conditions as well as frothy sentiment readings. On the monthly chart, bitcoin traced out a bullish cup-with-handle pattern from November 2021, breaking out and completing the formation in November 2024. The breakout occurred on above-average volume, a bullish sign. The crypto currency peaked during the month of January, pulled back to the breakout level earlier this month, and bounced nicely. Generally, a breakout followed by a successful retest are quite bullish -- and also very common during bull markets. (Mark Arbeter, CMT)

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).